Pau Herrero, United Kingdom
Imperial College London Electrical and Electronic EngineeringPresenter of 3 Presentations
THE PEPPER SYSTEM APPLICATION PROGRAM INTERFACE
- Pau Herrero, United Kingdom
- Joaquim Massana, Spain
- Yenny Leal, Spain
- Lucian Nita, Romania
- Parizad Avari, United Kingdom
- David Duce, United Kingdom
- Arantza Aldea, United Kingdom
- Pantelis Georgiou, United Kingdom
- José M. Fernández-real, Spain
- Mercè Fernández-balsells, Spain
- Nick Oliver, United Kingdom
- Beatriz Lopez, Spain
- Clare Martin, United Kingdom
ROBUST DETERMINATION OF THE OPTIMAL CONTINUOUS GLUCOSE MONITORING LENGTH OF INTERVENTION TO EVALUATE LONG-TERM GLYCAEMIC CONTROL
Abstract
Background and Aims
Previous studies suggest a minimum duration of ~14 days of continuous glucose monitoring (CGM) data are required for robust assessment of glucose control metrics in people with type 1 diabetes (T1D). However, this was derived from older CGM devices and the employed techniques required big datasets (>150 subjects) to achieve reliable results. In this work, we present a robust technique using data from newer generation sensors to determine if the minimum duration remains ~14 days. We also evaluate a larger set of glycaemic metrics.
Methods
CGM data from a 6-month randomised clinical trial in 25 adults with T1D was analysed. Eight glucose metrics were evaluated on different sliding time windows of durations ranging from one to 90 days. Then, the absolute percentage error was computed for each window incidence against the entire duration. Finally, the median (interquartile range) for each window length was calculated.
Results
The figure below shows the results corresponding to the metrics: percentage time in [70,180] mg/dL, and percentage time below 70 mg/dL. Note that the latter presents a much higher error and variance.
Conclusions
The duration of ~14 days of CGM data remains the minimum required for most of the evaluated metrics, but not for the ones related to hypoglycaemia, which require a much longer duration. The proposed technique can be employed in a smaller dataset to attain a high level of reliability.
A NOVEL HAND-HELD INTERFACE SUPPORTING THE SELF-MANAGEMENT OF TYPE 1 DIABETES
Abstract
Background and Aims
The novel ARISES app designed to be used by people with Type-1 diabetes incorporates a number of interface features designed to enhance its usability. One feature is a diary offering both focus-plus-context and historical views of medical data. Another is the novel use of context (Figure). A third is the smooth manual exploration (“What if . . ?”) of the effect of carbohydrate intake on predicted blood glucose level and recommended insulin dose.
Methods
Usability evaluation is of paramount importance and will take two forms. One is a full conventional clinical trial in the course of which a number of quantitative and qualitative usability outcomes will be observed. That will follow a pilot study to identify possible improvements. For this latter study, a novel concept called Circles of Affordance has been devised. It is economic and designed to show a user’s departure from optimum behaviour.
Results
Implementation of the interface is at an advanced stage and will be complete by November 2019. The Circles of Affordance diagram has been through initial tests based on a number of virtual scenarios.
Conclusions
Design of the smartphone app's interface has benefitted from feedback from both representative users and interface design specialists, and its implementation is almost complete. Plans are in place to carry out usability studies.